Infohealth sees sales growth due to diversification
The UK company is growing in the sector of specials drug manufacture
UK based Infohealth, which specialises in the development, licensing and commercialisation of medical drugs, has diversified its business. New funding has allowed the company to purchase licences for existing drugs, as well as invest in the design and development of licences for new drugs.
Established in 1999, Infohealth originally started as a chain of retail pharmacies, relying predominantly on NHS funded prescription business. During the recent economic downturn, the directors saw a need to diversify and a strategy was put into place to transform the company into specialists in drug manufacture. Funding has been provided by NatWest, backed by the UK Government’s Funding for Lending Scheme.
Infohealth Laboratories division offers the development and supply of customised, high value injectable drugs for hospital and specialist applications. The company creates new dosage and packaging forms that provide flexibility and ease-of-use for hospital physicians, pharmacists and patients.
Back in April, the company acquired the marketing authorisations, the trademarks and additional intellectual property right assets concerning injectable pharmaceuticals and other novel dosage forms, covering UK and global territories, from OI Sciences Ltd.
Raj Patel, Director at Infohealth said: ‘It’s a really challenging but exciting time for us right now. We’re putting a lot of changes in place to help secure the company’s future.’
Predicted sales this year are forecasted to see a six-fold increase as a direct result of its diversification.
